maxitrol suspension
novartis corporation (malaysia) sdn. bhd. - dexamethasone; neomycin sulphate; polymyxin b sulphate -
isopto maxidex 0.1% eye drops
alcon-scientific office - eye drops - 0.1 %
sprycel
bristol-myers squibb australia pty ltd - dasatinib -
sprycel
bristol-myers squibb (nz) limited - dasatinib 100mg; - film coated tablet - 100 mg - active: dasatinib 100mg excipient: croscarmellose sodium hyprolose lactose monohydrate magnesium stearate microcrystalline cellulose opadry white ys-1-18177-a - · sprycel® (dasatinib) is indicated for the treatment of adults aged 18 years or over with newly diagnosed chronic myeloid leukaemia (cml). · sprycel® (dasatinib) is indicated for the treatment of adults aged 18 years or over with chronic, accelerated or myeloid or lymphoid blast phase chronic myeloid leukaemia with resistance or intolerance to prior therapy including imatinib. · sprycel® (dasatinib) is indicated for the treatment of paediatric patients with philadelphia chromosome positive chronic myeloid leukaemia (cml) in the chronic phase
sprycel
bristol-myers squibb (nz) limited - dasatinib 20mg; - film coated tablet - 20 mg - active: dasatinib 20mg excipient: croscarmellose sodium hyprolose lactose monohydrate magnesium stearate microcrystalline cellulose opadry white ys-1-18177-a - · sprycel® (dasatinib) is indicated for the treatment of adults aged 18 years or over with newly diagnosed chronic myeloid leukaemia (cml). · sprycel® (dasatinib) is indicated for the treatment of adults aged 18 years or over with chronic, accelerated or myeloid or lymphoid blast phase chronic myeloid leukaemia with resistance or intolerance to prior therapy including imatinib. · sprycel® (dasatinib) is indicated for the treatment of paediatric patients with philadelphia chromosome positive chronic myeloid leukaemia (cml) in the chronic phase
sprycel
bristol-myers squibb (nz) limited - dasatinib 50mg; - film coated tablet - 50 mg - active: dasatinib 50mg excipient: croscarmellose sodium hyprolose lactose monohydrate magnesium stearate microcrystalline cellulose opadry white ys-1-18177-a - · sprycel® (dasatinib) is indicated for the treatment of adults aged 18 years or over with newly diagnosed chronic myeloid leukaemia (cml). · sprycel® (dasatinib) is indicated for the treatment of adults aged 18 years or over with chronic, accelerated or myeloid or lymphoid blast phase chronic myeloid leukaemia with resistance or intolerance to prior therapy including imatinib. · sprycel® (dasatinib) is indicated for the treatment of paediatric patients with philadelphia chromosome positive chronic myeloid leukaemia (cml) in the chronic phase
sprycel
bristol-myers squibb (nz) limited - dasatinib 70mg; - film coated tablet - 70 mg - active: dasatinib 70mg excipient: croscarmellose sodium hyprolose lactose monohydrate magnesium stearate microcrystalline cellulose opadry white ys-1-18177-a - · sprycel® (dasatinib) is indicated for the treatment of adults aged 18 years or over with newly diagnosed chronic myeloid leukaemia (cml). · sprycel® (dasatinib) is indicated for the treatment of adults aged 18 years or over with chronic, accelerated or myeloid or lymphoid blast phase chronic myeloid leukaemia with resistance or intolerance to prior therapy including imatinib. · sprycel® (dasatinib) is indicated for the treatment of paediatric patients with philadelphia chromosome positive chronic myeloid leukaemia (cml) in the chronic phase
nexavar tablet
bayer inc - sorafenib (sorafenib tosylate) - tablet - 200mg - sorafenib (sorafenib tosylate) 200mg - antineoplastic agents
kaletra lopinavir and ritonavir tablet film coated
cardinal health - lopinavir (unii: 2494g1jf75) (lopinavir - unii:2494g1jf75) - lopinavir 200 mg
sprycel dasatinib 100 mg tablet bottle
bristol-myers squibb australia pty ltd - dasatinib, quantity: 100 mg - tablet, film coated - excipient ingredients: hyprolose; microcrystalline cellulose; croscarmellose sodium; magnesium stearate; lactose monohydrate; titanium dioxide; hypromellose; macrogol 400 - sprycel is indicated for the treatment of adults aged 18 years or over with: - newly diagnosed philadelphia chromosome positive (ph+) chronic myeloid leukaemia in the chronic phase. - chronic, accelerated or myeloid or lymphoid blast phase chronic myeloid leukameia with resistance or intolerance to prior therapy including imatinib. - newly diagnosed philadelphia chromosome positive acute lymphoblastic leukameia integrated with chemotherapy. - philadelphia chromosome positive acute lymphoblastic leukamia with resistance or intolerance to prior therapy.,sprycel is indicated for the treatment of paediatric patients with: - ph+ cml in the chronic phase. - newly diagnosed ph+ all in combination with chemotherapy.